Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.

Migden MR, Khushalani NI, Chang ALS, Lewis KD, Schmults CD, Hernandez-Aya L, Meier F, Schadendorf D, Guminski A, Hauschild A, Wong DJ, Daniels GA, Berking C, Jankovic V, Stankevich E, Booth J, Li S, Weinreich DM, Yancopoulos GD, Lowy I, Fury MG, Rischin D.

Lancet Oncol. 2020 Feb;21(2):294-305. doi: 10.1016/S1470-2045(19)30728-4. Epub 2020 Jan 14.

PMID:
31952975
2.

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.

Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Krepler C, Ibrahim N, Marreaud S, van Akkooi A, Robert C, Suciu S.

JAMA Oncol. 2020 Jan 2. doi: 10.1001/jamaoncol.2019.5570. [Epub ahead of print]

3.

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.

Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ, Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez-Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA.

Cancer Discov. 2020 Jan;10(1):40-53. doi: 10.1158/2159-8290.CD-19-0980. Epub 2019 Nov 15.

4.

Long-Term Outcomes with 3-Dimensional Conformal External Beam Accelerated Partial Breast Irradiation.

Kennedy WR, Roach MC, Thomas MA, Ochoa L, Altman MB, Hernandez-Aya LF, Cyr AE, Margenthaler JA, Zoberi I.

Pract Radiat Oncol. 2019 Sep 18. pii: S1879-8500(19)30271-1. doi: 10.1016/j.prro.2019.09.007. [Epub ahead of print]

PMID:
31541717
5.

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJ, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Lupinacci R, Krepler C, Ibrahim N, Kicinski M, Marreaud S, van Akkooi AC, Suciu S, Robert C.

Eur J Cancer. 2019 Jul;116:148-157. doi: 10.1016/j.ejca.2019.05.020. Epub 2019 Jun 11.

PMID:
31200321
6.

Treatment response as predictor for brain metastasis in triple negative breast cancer: A score-based model.

Gabani P, Weiner AA, Hernandez-Aya LF, Khwaja S, Roach MC, Ochoa LL, Mullen D, Thomas MA, Matesa MA, Margenthaler JA, Cyr AE, Naughton MJ, Ma C, Sanati S, Zoberi I.

Breast J. 2019 May;25(3):363-372. doi: 10.1111/tbj.13230. Epub 2019 Mar 28.

PMID:
30920124
7.

Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer.

Xi J, Oza A, Thomas S, Ademuyiwa F, Weilbaecher K, Suresh R, Bose R, Cherian M, Hernandez-Aya L, Frith A, Peterson L, Luo J, Krishnamurthy J, Ma CX.

J Natl Compr Canc Netw. 2019 Feb;17(2):141-147. doi: 10.6004/jnccn.2018.7094.

8.

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.

Johnson DB, Bordeaux J, Kim JY, Vaupel C, Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, Hernandez-Aya LF, Dimou A, Funchain P, Smithy J, Witte JS, McKee SB, Ko J, Wrangle JM, Dabbas B, Tangri S, Lameh J, Hall J, Markowitz J, Balko JM, Dakappagari N.

Clin Cancer Res. 2018 Nov 1;24(21):5250-5260. doi: 10.1158/1078-0432.CCR-18-0309. Epub 2018 Jul 18.

9.

Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes.

Gabani P, Fischer-Valuck BW, Johanns TM, Hernandez-Aya LF, Keller JW, Rich KM, Kim AH, Dunn GP, Robinson CG, Chicoine MR, Huang J, Abraham CD.

Radiother Oncol. 2018 Aug;128(2):266-273. doi: 10.1016/j.radonc.2018.06.017. Epub 2018 Jun 27.

PMID:
29960685
10.

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.

Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG.

N Engl J Med. 2018 Jul 26;379(4):341-351. doi: 10.1056/NEJMoa1805131. Epub 2018 Jun 4.

11.

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suciu S, Robert C.

N Engl J Med. 2018 May 10;378(19):1789-1801. doi: 10.1056/NEJMoa1802357. Epub 2018 Apr 15.

12.

Chemotherapy principles of managing stage IV breast cancer in the United States.

Hernandez-Aya LF, Ma CX.

Chin Clin Oncol. 2016 Jun;5(3):42. doi: 10.21037/cco.2016.04.01. Epub 2016 Apr 14. Review.

13.

Low-Cost Intervention to Increase Influenza Vaccination Rate at a Comprehensive Cancer Center.

Grivas PD, Devata S, Khoriaty R, Boonstra PS, Ruch J, McDonnell K, Hernandez-Aya L, Wilfong J, Smerage J, Ison MG, Eisenberg JNS, Silveira M, Cooney KA, Worden FP.

J Cancer Educ. 2017 Dec;32(4):871-877. doi: 10.1007/s13187-016-1017-2.

PMID:
27055536
14.

Why Chemotherapy Should be Given Early for Men with Metastatic Prostate Cancer.

Hernandez-Aya LF, Hussain M.

Am Soc Clin Oncol Educ Book. 2015:e263-9. doi: 10.14694/EdBook_AM.2015.35.e263.

15.

A meta-analysis on the prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in patients with Chronic Obstructive Pulmonary Disease.

Donath E, Chaudhry A, Hernandez-Aya LF, Lit L.

Respir Med. 2013 Sep;107(9):1385-92. doi: 10.1016/j.rmed.2013.05.004. Epub 2013 Jun 12. Review.

16.

Adjuvant systemic therapies in breast cancer.

Hernandez-Aya LF, Gonzalez-Angulo AM.

Surg Clin North Am. 2013 Apr;93(2):473-91. doi: 10.1016/j.suc.2012.12.002. Epub 2013 Feb 8. Review.

PMID:
23464697
17.

Triple-negative breast cancer is not a contraindication for breast conservation.

Adkins FC, Gonzalez-Angulo AM, Lei X, Hernandez-Aya LF, Mittendorf EA, Litton JK, Wagner J, Hunt KK, Woodward WA, Meric-Bernstam F.

Ann Surg Oncol. 2011 Oct;18(11):3164-73. doi: 10.1245/s10434-011-1920-z. Epub 2011 Sep 27.

18.

Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers.

Raghav KP, Hernandez-Aya LF, Lei X, Chavez-Macgregor M, Meric-Bernstam F, Buchholz TA, Sahin A, Do KA, Hortobagyi GN, Gonzalez-Angulo AM.

Cancer. 2012 Mar 15;118(6):1498-506. doi: 10.1002/cncr.26431. Epub 2011 Aug 11.

19.

Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer.

Hernandez-Aya LF, Chavez-Macgregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, Sahin AA, Do KA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM.

J Clin Oncol. 2011 Jul 1;29(19):2628-34. doi: 10.1200/JCO.2010.32.1877. Epub 2011 May 23.

20.

Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.

Hernandez-Aya LF, Gonzalez-Angulo AM.

Oncologist. 2011;16(4):404-14. doi: 10.1634/theoncologist.2010-0402. Epub 2011 Mar 15. Review.

Supplemental Content

Loading ...
Support Center